Baird analyst Colleen Kusy raised the firm’s price target on Cogent Biosciences (COGT) to $9 from $7 and keeps a Neutral rating on the shares. The firm updated its model following the release of SUMMIT data in Non-AdvSM which was better than the worst case scenarion but worse than the best case.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COGT:
- Promising Outlook for Cogent Biosciences: Bezuclastinib’s Potential in Systemic Mastocytosis and Beyond
- Cogent Biosciences Receives Buy Rating on Promising Trial Results and Market Potential
- Musk to launch new political party, Trump threatens BRICS tariff: Morning Buzz
- Cogent Biosciences price target raised to $18 from $16 at Leerink
- Cogent Biosciences price target raised at Jefferies after ‘home run’ data